Enhanced Immunogenic Murine Tumor Cell Lines
This invention comprises novel murine tumor cell lines genetically engineered to express an active form of the cytokine interleukin-33 (IL-33). By modifying these cells, the technology significantly enhances the body's natural antitumor immune response.
Description
The technology utilizes advanced genetic engineering to introduce an active version of mouse IL-33 into established tumor cell lines, specifically 4T1 and B16F0. By expressing this potent cytokine, the otherwise non-immunogenic tumor cells are transformed into immunogenic targets that actively recruit and activate the immune system. This approach modifies the tumor microenvironment to promote a robust anti-tumor response mediated by CD8+ T cells and Natural Killer (NK) cells. By effectively "marking" the tumor cells, this method provides a superior model for studying immune-mediated tumor suppression and developing potential immunotherapeutic strategies.Applications
- Cancer Immunotherapy Development: Used by pharmaceutical companies to screen and validate novel immunotherapy drugs.- Drug Discovery Research: Serves as a robust model for preclinical testing of combination therapies.
- Academic and Clinical Research: Facilitates high-level investigation into the mechanics of the tumor microenvironment.
- Biotechnology Assay Development: Utilized for developing high-throughput assays to measure immune response against specific tumor types.
Advantages
- Enhanced Immunogenicity: Effectively transforms standard tumor cell lines into highly immunogenic targets.- Targeted Immune Activation: Specifically modifies the tumor microenvironment to trigger a more aggressive immune response.
- In-Vivo Efficacy: Demonstrated ability to inhibit tumor growth through the recruitment of CD8+ T cells and NK cells.
- Research Superiority: Provides a more accurate and responsive model for cancer immunotherapy studies compared to unmodified cell lines.
- Novel Therapeutic Platform: Serves as a foundational tool for investigating cytokine-based cancer interventions.